BioPharma
Enhertu Priority Review in HER2-Positive Early Breast Cancer
The supplemental Biologics License Application - sBLA for Enhertu - trastuzumab deruxtecan by AstraZeneca and Daiichi Sankyo has been accepted as well as granted Priority Review in the U.S. when it comes to the treatment of adult patients with...
Business & Industry
Taiwan Launches $755M Pharma Resilience Plan to Boost Supply
Taiwan is preparing a four-year national pharmaceutical resilience preparedness program designed to strengthen its domestic drug supply, supported by a 24 billion new Taiwan dollar ($755 million) investment. The initiative is intended to reinforce the country’s ability to maintain...
Business & Industry
Norgine Invests £23m to Expand Hengoed Pharma Facility in UK
Norgine has confirmed a £23 million ($31 million) investment in its manufacturing facility in Hengoed, Wales, increasing the total capital directed toward the site to more than £50 million ($67 million) since 2022. The move is intended to strengthen...
News
Oral Microbiome Research and Its Implications for Future Therapeutics
Over the past decade, microbiome science has reshaped how researchers understand human health.
While much of the early focus centered on the gut, attention is increasingly turning toward another complex microbial ecosystem with significant systemic implications: the oral microbiome.
Home to...
BioPharma
Sanofi Secures Global Rights to Rovadicitinib in $1.53B Deal
Sanofi has committed up to $1.53 billion to obtain global rights to a novel therapy from Sino Biopharmaceutical, adding a first-in-class JAK/ROCK inhibitor to its hematology and immunology pipeline. The French pharmaceutical group will make an upfront payment of...
Business & Industry
UK Invests £47.8M to Expand NHS Clinical Trial Capacity
The UK government has announced nearly £50 million in funding aimed at strengthening the NHS’s capacity to conduct commercial research projects and clinical trials supported partly by the pharmaceutical industry. The investment is intended to supply critical research and...
Business & Industry
CMS Extends GENEROUS MFN Drug Pricing Deadline to April
The Centers for Medicare & Medicaid Services (CMS) in the US has moved to extend the enrolment window for its GENEROUS pilot programme, an initiative aimed at introducing most-favoured-nation (MFN) pricing for outpatient drugs reimbursed by Medicaid. The agency...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.